Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

401 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Myelodysplasia-associated immunophenotypic alterations of bone marrow cells in myeloma: are they present at diagnosis or are they induced by lenalidomide?
Matarraz S, Paiva B, Diez-Campelo M, López-Corral L, Pérez E, Mateos MV, Giraldo P, Hernández MT, San Miguel JF, Orfao A; GEM Grupo Español de MM/Programa para el Estudio de la Terapéutica en Hemopatías Malignas Co-operative Study Groups. Matarraz S, et al. Among authors: giraldo p. Haematologica. 2012 Oct;97(10):1608-11. doi: 10.3324/haematol.2012.064121. Epub 2012 Apr 17. Haematologica. 2012. PMID: 22511492 Free PMC article.
High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA.
Bladé J, Rosiñol L, Sureda A, Ribera JM, Díaz-Mediavilla J, García-Laraña J, Mateos MV, Palomera L, Fernández-Calvo J, Martí JM, Giraldo P, Carbonell F, Callís M, Trujillo J, Gardella S, Moro MJ, Barez A, Soler A, Font L, Fontanillas M, San Miguel J; Programa para el Estudio de la Terapéutica en Hemopatía Maligna (PETHEMA). Bladé J, et al. Among authors: giraldo p. Blood. 2005 Dec 1;106(12):3755-9. doi: 10.1182/blood-2005-03-1301. Epub 2005 Aug 16. Blood. 2005. PMID: 16105975 Free article. Clinical Trial.
Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation.
Bendandi M, Rodríguez-Calvillo M, Inogés S, López-Díaz de Cerio A, Pérez-Simón JA, Rodríguez-Caballero A, García-Montero A, Almeida J, Zabalegui N, Giraldo P, San Miguel J, Orfao A. Bendandi M, et al. Among authors: giraldo p. Leuk Lymphoma. 2006 Jan;47(1):29-37. doi: 10.1080/10428190500272473. Leuk Lymphoma. 2006. PMID: 16321824 Clinical Trial.
Impact of trisomy 12, del(13q), del(17p), and del(11q) on the immunophenotype, DNA ploidy status, and proliferative rate of leukemic B-cells in chronic lymphocytic leukemia.
Quijano S, López A, Rasillo A, Sayagués JM, Barrena S, Sánchez ML, Teodosio C, Giraldo P, Giralt M, Pérez MC, Romero M, Perdiguer L, Orfao A. Quijano S, et al. Among authors: giraldo p. Cytometry B Clin Cytom. 2008 May;74(3):139-49. doi: 10.1002/cyto.b.20390. Cytometry B Clin Cytom. 2008. PMID: 18061951 Free article.
Association between the proliferative rate of neoplastic B cells, their maturation stage, and underlying cytogenetic abnormalities in B-cell chronic lymphoproliferative disorders: analysis of a series of 432 patients.
Quijano S, López A, Rasillo A, Barrena S, Luz Sánchez M, Flores J, Fernández C, Sayagués JM, Osuna CS, Fernández N, González M, Giraldo P, Giralt M, Pérez MC, Martin-Antoran JM, Gutiérrez O, Perdiguer L, Díaz Mediavilla J, González Silva M, Asensio Del Rio A, Cerveró C, Guerra JL, Butrón R, García Mdel C, Almeida J, Orfao A. Quijano S, et al. Among authors: giraldo p. Blood. 2008 May 15;111(10):5130-41. doi: 10.1182/blood-2007-10-119289. Epub 2008 Mar 12. Blood. 2008. PMID: 18337555 Free article.
The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia.
Santamaría C, Chillón MC, García-Sanz R, Balanzategui A, Sarasquete ME, Alcoceba M, Ramos F, Bernal T, Queizán JA, Peñarrubia MJ, Giraldo P, San Miguel JF, Gonzalez M. Santamaría C, et al. Among authors: giraldo p. Haematologica. 2008 Dec;93(12):1797-805. doi: 10.3324/haematol.13214. Epub 2008 Sep 24. Haematologica. 2008. PMID: 18815192 Free article.
Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia.
Santamaría CM, Chillón MC, García-Sanz R, Pérez C, Caballero MD, Ramos F, de Coca AG, Alonso JM, Giraldo P, Bernal T, Queizán JA, Rodriguez JN, Fernández-Abellán P, Bárez A, Peñarrubia MJ, Balanzategui A, Vidriales MB, Sarasquete ME, Alcoceba M, Díaz-Mediavilla J, San Miguel JF, Gonzalez M. Santamaría CM, et al. Among authors: giraldo p. Blood. 2009 Jul 2;114(1):148-52. doi: 10.1182/blood-2008-11-187724. Epub 2009 Apr 27. Blood. 2009. PMID: 19398719 Free article.
High FOXO3a expression is associated with a poorer prognosis in AML with normal cytogenetics.
Santamaría CM, Chillón MC, García-Sanz R, Pérez C, Caballero MD, Ramos F, de Coca AG, Alonso JM, Giraldo P, Bernal T, Queizán JA, Rodriguez JN, Fernández-Abellán P, Bárez A, Peñarrubia MJ, Vidriales MB, Balanzategui A, Sarasquete ME, Alcoceba M, Díaz-Mediavilla J, San Miguel JF, Gonzalez M. Santamaría CM, et al. Among authors: giraldo p. Leuk Res. 2009 Dec;33(12):1706-9. doi: 10.1016/j.leukres.2009.04.024. Epub 2009 May 19. Leuk Res. 2009. PMID: 19457552
BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML).
Santamaría C, Chillón MC, García-Sanz R, Pérez C, Caballero MD, Mateos MV, Ramos F, de Coca AG, Alonso JM, Giraldo P, Bernal T, Queizán JA, Rodríguez JN, Puig N, Balanzategui A, Sarasquete ME, Alcoceba M, Díaz-Mediavilla J, San Miguel J, González M. Santamaría C, et al. Among authors: giraldo p. Ann Hematol. 2010 May;89(5):453-8. doi: 10.1007/s00277-009-0864-x. Epub 2009 Nov 27. Ann Hematol. 2010. PMID: 19943049
Long FLT3 internal tandem duplications and reduced PML-RARα expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients.
Chillón MC, Santamaría C, García-Sanz R, Balanzategui A, Sarasquete ME, Alcoceba M, Marín L, Caballero MD, Vidriales MB, Ramos F, Bernal T, Díaz-Mediavilla J, García de Coca A, Peñarrubia MJ, Queizán JA, Giraldo P, San Miguel JF, González M. Chillón MC, et al. Among authors: giraldo p. Haematologica. 2010 May;95(5):745-51. doi: 10.3324/haematol.2009.015073. Epub 2010 Feb 4. Haematologica. 2010. PMID: 20133893 Free PMC article.
401 results